{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:13Z","timestamp":1778780113158,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T00:00:00Z","timestamp":1308700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T00:00:00Z","timestamp":1308700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10637-011-9706-5","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T06:30:01Z","timestamp":1308637801000},"page":"1540-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Su Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongtae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Seok","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,22]]},"reference":[{"issue":"4","key":"9706_CR1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3346\/jkms.2002.17.4.457","volume":"17","author":"DH Lee","year":"2002","unstructured":"Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR (2002) Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 17(4):457\u2013462","journal-title":"J Korean Med Sci"},{"issue":"2","key":"9706_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4143\/crt.2004.36.2.103","volume":"36","author":"HR Shin","year":"2004","unstructured":"Shin HR, Jung KW, Won YJ, Park JG (2004) 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Canc Res Treat 36(2):103\u2013114. doi:10.4143\/crt.2004.36.2.103","journal-title":"Canc Res Treat"},{"issue":"2","key":"9706_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","volume":"11","author":"G Pelletier","year":"1990","unstructured":"Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P et al (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11(2):181\u2013184","journal-title":"J Hepatol"},{"issue":"1","key":"9706_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","volume":"29","author":"G Pelletier","year":"1998","unstructured":"Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29(1):129\u2013134","journal-title":"J Hepatol"},{"issue":"11","key":"9706_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/j.1365-2036.2006.02932.x","volume":"23","author":"PM Lopez","year":"2006","unstructured":"Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: evidence-based management of hepatocellular carcinoma\u2014an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23(11):1535\u20131547. doi:10.1111\/j.1365-2036.2006.02932.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"9706_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429\u2013442. doi:10.1053\/jhep.2003.50047","journal-title":"Hepatology"},{"issue":"5","key":"9706_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Canc Chemother Pharmacol 59(5):561\u2013574. doi:10.1007\/s00280-006-0393-4","journal-title":"Canc Chemother Pharmacol"},{"issue":"19","key":"9706_CR8","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Canc Res 64(19):7099\u20137109. doi:10.1158\/0008-5472.CAN-04-1443","journal-title":"Canc Res"},{"issue":"11","key":"9706_CR9","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","volume":"11","author":"R Iyer","year":"2010","unstructured":"Iyer R, Fetterly G, Lugade A, Thanavala Y (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11(11):1943\u20131955. doi:10.1517\/14656566.2010.496453","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"9706_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390. doi:10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"1","key":"9706_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. doi:10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"9706_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","volume":"61","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Canc Chemother Pharmacol 61(4):535\u2013548. doi:10.1007\/s00280-007-0639-9","journal-title":"Canc Chemother Pharmacol"},{"issue":"3","key":"9706_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/13543780902729412","volume":"18","author":"MW Saif","year":"2009","unstructured":"Saif MW, Syrigos KN, Katirtzoglou NA (2009) S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18(3):335\u2013348. doi:10.1517\/13543780902729412","journal-title":"Expert Opin Investig Drugs"},{"issue":"1\u20132","key":"9706_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000151614","volume":"75","author":"K Uka","year":"2008","unstructured":"Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, Azakami T et al (2008) Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 75(1\u20132):8\u201316. doi:10.1159\/000151614","journal-title":"Oncology"},{"issue":"8","key":"9706_CR15","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/cncr.23356","volume":"112","author":"M Nakamura","year":"2008","unstructured":"Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S et al (2008) Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 112(8):1765\u20131771. doi:10.1002\/cncr.23356","journal-title":"Cancer"},{"issue":"80","key":"9706_CR16","first-page":"2315","volume":"54","author":"Z Morise","year":"2007","unstructured":"Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M (2007) S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology 54(80):2315\u20132318","journal-title":"Hepatogastroenterology"},{"key":"9706_CR17","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1111\/j.1349-7006.2010.01730.x","volume":"101","author":"J Furuse","year":"2010","unstructured":"Furuse J, Okusaka T, Kaneko S, Kudo M, Nakachi K, Ueno H et al (2010) Phase I\/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Canc Sci 101:2606\u20132611. doi:10.1111\/j.1349-7006.2010.01730.x","journal-title":"Canc Sci"},{"issue":"12","key":"9706_CR18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.5414\/CPP41616","volume":"41","author":"M Heim","year":"2003","unstructured":"Heim M, Sharifi M, Hilger RA, Scheulen ME, Seeber S, Strumberg D (2003) Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 41(12):616\u2013617","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"9706_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Canc Sci 99(1):159\u2013165. doi:10.1111\/j.1349-7006.2007.00648.x","journal-title":"Canc Sci"},{"issue":"26","key":"9706_CR20","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293\u20134300. doi:10.1200\/JCO.2005.01.3441","journal-title":"J Clin Oncol"},{"key":"9706_CR21","unstructured":"European Medicines Agency: Sorafenib(nexavar) summary of product characteristics pp.6 [online]. Available from URL: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR>_-_Product_Information\/human\/000690\/WC500027704.pdf"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9706-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9706-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:28:56Z","timestamp":1678559336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9706-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,22]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["9706"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9706-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,22]]},"assertion":[{"value":"11 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}